Drug Trial Radar · NCT00720798
An Extension Study of Tocilizumab (Myeloma Receptor Antibody [MRA]) in Patients Completing Treatment in Tocilizumab Core Studies
Last checked: Nov 20, 2026Latest source record: Sep 30, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
2,067
Actual
Start
Sep 2005
Primary completion
Apr 2013
Study completion Apr 2013
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Jul 23, 2008
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This single-arm study evaluated the long-term efficacy and safety of tocilizumab in participants who had completed treatment in the tocilizumab core studies (NCT00106522 \[Roche protocol WA18062\], NCT00106574 \[Roche protocol WA18063\], and NCT00109408 \[Roche protocol WA17824\]) of adults with rheumatoid arthritis. Participants received tocilizumab alone or in combination with standard anti-rheumatic treatment.
Conditions
- Rheumatoid Arthritis
Interventions
TocilizumabDrug
For participants weighing \> 100 kg, the maximum dose of tocilizumab was 800 mg. Tocilizumab was supplied as a sterile solution in vials.
Disease-modifying anti-rheumatic drugsDrug
Disease-modifying anti-rheumatic drugs included methotrexate, chloroquine, hydroxychloroquine, parenteral gold, sulfasalazine, azathioprine, and leflunomide. These drugs could be used alone or in combination, except for the combination of methotrexate and leflunomide, which was not allowed.
Non-steroidal anti-inflammatory drugsDrug
Participants could be treated with non-steroidal anti-inflammatory drugs up to the maximum recommended dose throughout the study. The choice and doses of non-steroidal anti-inflammatory drugs were at the discretion of the investigator.
Oral corticosteroidsDrug
Oral corticosteroids (≤ 10 mg/day) were permitted during the study.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With ≥ 1 Adverse EventTime frame: Baseline to the end of the study (up to 7 years, 7 months)
Locations
295 sites in 34 countries. Site status is shown where the registry gives one.
Site not named
Birmingham, Alabama
Site not named
Huntsville, Alabama
Site not named
Mesa, Arizona
Site not named
Paradise Valley, Arizona
Site not named
Peoria, Arizona
Site not named
Scottsdale, Arizona
Site not named
Scottsdale, Arizona
Site not named
Tucson, Arizona
Site not named
Tucson, Arizona
Site not named
Little Rock, Arkansas
Site not named
Anaheim, California
Site not named
Long Beach, California
Site not named
Long Beach, California
Site not named
Los Angeles, California
Site not named
Los Angeles, California
Site not named
Palm Desert, California
Site not named
Palm Springs, California
Site not named
Palo Alto, California
Site not named
San Diego, California
Site not named
San Diego, California
Site not named
San Jose, California
Site not named
San Leandro, California
Site not named
Santa Maria, California
Site not named
Torrance, California
Site not named
Upland, California
Site not named
Colorado Springs, Colorado
Site not named
Newark, Delaware
Site not named
Aventura, Florida
Site not named
Delray Beach, Florida
Site not named
Fort Lauderdale, Florida
Site not named
Palm Habor, Florida
Site not named
Palm Harbor, Florida
Site not named
Sarasota, Florida
Site not named
Tampa, Florida
Site not named
Tampa, Florida
Site not named
West Palm Beach, Florida
Site not named
Atlanta, Georgia
Site not named
Boise, Idaho
Site not named
Idaho Falls, Idaho
Site not named
Meridian, Idaho
Showing 40 of 295 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.